(Adnkronos) - In questo numero:
La Società italiana di Neurologia presenta a Roma il decalogo per la salute del cervello
Malattie cardiovascolari, gli esperti raccomandano maggiore attenzione ai soggetti ad alto rischio
Anticorpo monoclonale tezepèlumab efficace in sinusite cronica con poliposi nasale oltre che in asma grave
Presentato il manifesto per l’umanizzazione delle cure in oncologia
Esperienze pre-morte, un convegno per un approccio scientifico
Commissione europea approva ampliamento indicazione mirikìzumab in malattia di Crohn. Gli esperti, nuova opportunità di cura
Tumore al seno metastatico, estesa indicazione sacituzumab govitecan a sottotipi HR+/HER2- e triplo negativo in II linea
La Società italiana di Neurologia presenta a Roma il decalogo per la salute del cervello
Malattie cardiovascolari, gli esperti raccomandano maggiore attenzione ai soggetti ad alto rischio
Anticorpo monoclonale tezepèlumab efficace in sinusite cronica con poliposi nasale oltre che in asma grave
Presentato il manifesto per l’umanizzazione delle cure in oncologia
Esperienze pre-morte, un convegno per un approccio scientifico
Commissione europea approva ampliamento indicazione mirikìzumab in malattia di Crohn. Gli esperti, nuova opportunità di cura
Tumore al seno metastatico, estesa indicazione sacituzumab govitecan a sottotipi HR+/HER2- e triplo negativo in II linea
Category
🗞
NewsTranscript
00:00In this issue, the Italian Society of Neurology presents in Rome the Decalogue for the Health of the Brain.
00:18Cardiovascular diseases, experts recommend more attention to high-risk subjects.
00:24Monoclonal antibody Tezepelumab, effective in chronic sinusitis with nasal polyposis, as well as in severe asthma.
00:32Presented the Manifesto for the Humanization of Oncology Cures.
00:36And again, pre-death experiences, an agreement for a scientific approach.
00:41The European Commission approves the expansion of the Mirichizumab indication in Crohn's disease.
00:47Experts, new opportunity for treatment.
00:50Metastatic breast tumor.
00:52Sacituzumab Govideccana indication.
00:55Has subtypes HR positive and R2 negative.
00:58And triple negative in the second line.
01:07Prevent pathologies and guarantee mental well-being.
01:10It is with this objective that the Italian Society of Neurology,
01:13at the One Brain One Health Convention,
01:15organized during the World Brain Week 2025,
01:19presented to the Ministry of Health in Rome
01:22a decalogue to respond 360 degrees to the crucial challenge of the health of the brain.
01:28At the meeting, the Italian Strategy for the Health of the Brain 2024-2031 was also discussed
01:35and the Italian Alliance for the Health of the Brain was launched.
01:39An organization structured by One Brain One Health and Italian Brain Health Strategy.
01:44The decalogue serves to inform people that preventing brain diseases
01:50and preserving the health of the brain can be done
01:54and can be done through an attention to lifestyles, but not only.
01:59We believe that it is now that citizenship, citizens,
02:04activate in terms of proactive medicine a series of attentions,
02:09also from a physical point of view.
02:11There are many diseases and these diseases sometimes occur in a sudden way.
02:15It is important to do an early diagnosis, but at the same time it is also important
02:19where there is a disease to put in place precautions, changes in lifestyles
02:24that can also positively influence the course of diseases.
02:28The Italian Society of Gerontology and Geriatry is engaged in the writing of a manifesto
02:33dedicated to the prevention of dementia,
02:35in which the main factors responsible for cognitive decline are identified.
02:40So we developed a dodecalogue that sees in the first place the prevention of delirium,
02:47which is a very important psychiatric manifestation in the geriatric age,
02:51especially in the hospitalized patient.
02:53Very important because this event, that is, the development of this psychotic manifestation
02:58in the elderly patient, is an important determinant of mortality.
03:03And not only mortality, but also the development of dementia.
03:08It is also essential to talk about mental health.
03:11As underlined by the WHO, in fact, it is important to adopt a global approach to health.
03:17The Ministry of Health and Minister Lazio Schillaci have given great importance
03:21to the theme of mental health and brain well-being.
03:24Let us remember the institution of the table of mental health,
03:28which has been working for almost two years now
03:30and is finally working on updating the national mental health plan.
03:36Let us remember the economic commitment that this government is investing in brain health,
03:41for example, the Alzheimer's Fund.
03:43It is clear that the change must be prospective.
03:46It is necessary that the government, therefore the legislator,
03:49as well as the minister and the ministry,
03:52approach brain health in an integrated way.
03:56We must not only pay attention to prevention,
03:59to early diagnosis and to treatment,
04:01because if the brain is well, the body is well,
04:04the human being knows well.
04:11There are more than one million patients at high risk of cardiovascular disease in Italy.
04:15Eight out of ten do not meet safety goals based on international guidelines.
04:20Cardiologists who participated in the Voices for Silencing event,
04:24organized by Novartis in Milan,
04:27talked about the management of the cardiovascular patient and much more.
04:32There is a very large population that is at very high risk
04:36and has fortunately never undergone an acute cardiovascular event.
04:40The challenge for the prevention of tomorrow and already of today
04:44is to intervene on this pool of subjects.
04:48These patients, as we need them today,
04:50and we can also treat them in a reimbursable regime as best we can
04:55for the containment of the lipid risk and not only.
04:59Obviously, this is for our activity as cardiologists
05:04the topic that today has become central, I would say,
05:09for the future cardiovascular prevention strategy.
05:12It is necessary to spread 360 degrees the culture of prevention of cardiovascular diseases,
05:18responsible every year in Italy of more than 224,000 deaths.
05:23As for the tools that we can use,
05:28obviously there are classic tools,
05:32which are those of meetings, ECMs,
05:35in which to discuss what are the indications of the guidelines
05:38and above all to give operational flowcharts
05:41on how to implement these guidelines,
05:44but there are then a whole series of other possible tools.
05:48The audits that have given us great satisfaction,
05:51such as AMCO, observational research
05:54and then certainly there are new technologies,
05:58for example apps that can give alerts
06:02both to cardiologists, to doctors, to patients
06:06on the non-reaching of the targets and on the measures
06:09that can be taken to instead try to reach them.
06:13There is still a gap between the recommendations of the guidelines
06:16and the real management of patients.
06:18What must be updated is the possibility for doctors to reach the goals
06:22and this can be done in two ways, essentially.
06:25One with an important education, which is often missing,
06:29especially in colleagues of general medicine,
06:31but also in specialties, this must be recognized,
06:35but also the regulatory framework, that is, many of the limits
06:39of our ability to reach these therapeutic goals
06:42are linked to the prescribability of drugs,
06:45especially innovative drugs.
06:47There are reasons for this, of course,
06:49but these reasons must not exceed the patient's interest.
06:53So it is very important that there is a continuous discussion with authorities
06:56to try to make it possible to access these innovative drugs
07:00to reach therapeutic goals
07:02and this will facilitate the achievement of therapeutic goals.
07:05In cardiovascular diseases, prevention remains an essential starting point.
07:10Today we have available diagnostic tests
07:14that can certainly help to prevent and recognize
07:20the risk of cardiovascular disease.
07:24Dialogue between doctor and patient is essential.
07:28It is of enormous value to help the patient
07:32to be adherent to therapy,
07:35to follow and recognize symptoms,
07:38also when there are acute phases,
07:41so you have to go to the emergency room.
07:50The impact of severe asthma and chronic rhinosinusitis
07:52with nasal polyposis on the quality of life of those who suffer
07:55can be very important, both from a physical and psychological point of view.
07:59It involves limitations in daily activities,
08:01sleep disorders and sometimes even anxiety or depression.
08:04According to the data of the Italian Registry of Severe Asthma,
08:0742% of subjects affected by this pathology
08:10also suffer from nasal polyposis.
08:12To mediate the immune response of the inflammatory type
08:15due to the damage of the epithelial barrier
08:17caused by allergens, pollution or virus,
08:19there are in both pathologies a particular type of cytokines,
08:23the alarmines, among these the TSLP plays a fundamental role.
08:27The anti-TSLP, that is the monoclonal antibody
08:31that blocks this alarmine, the tezepelum,
08:35is currently available for bronchial asthma,
08:40but recently at the American Academy World Allergy Organization in San Diego
08:46last week and at the same time at the New England Journal of Medicine
08:52the data on the effectiveness of tezepelum
08:57also in chronic rhinosinusitis with nasal polyposis were released,
09:03and it was an extremely interesting data
09:06because the effectiveness was demonstrated
09:09on all the parameters that have been studied.
09:13This is the study of Phase 3 Waypoint
09:16that shows how tezepelumab can be a therapeutic option
09:19of great relevance also for the treatment of chronic rhinosinusitis
09:23with nasal polyposis.
09:25Tezepelumab in this study has been shown to be effective
09:29in reducing the size of the polyps,
09:32in significantly improving olfactory sensitivity
09:37and in reducing other symptoms associated with the disease.
09:42In addition, tezepelumab in this particular category of patients
09:47who are severely ill,
09:50has been shown to be effective in reducing, for 98% of them,
09:56the need for a new surgical intervention
09:59and for 88% of them to reduce the need for systemic corticosteroids.
10:05Tezepelumab, the only anti-TSLP biological drug approved
10:09capable of acting at the epithelial barrier level,
10:12is the result of the commitment and research and development of AstraZeneca.
10:16AstraZeneca has always been committed to research and development,
10:20especially in the field of respiratory and immunological pathologies.
10:25Tezepelumab is a pioneering approach by AstraZeneca
10:31in targeting TSLP as an epithelial cytokine
10:36on the brink of a inflammatory cascade.
10:39This new molecule has already shown to be extremely effective
10:44and safe in the field of severe asthma
10:46and today, thanks to the results of the Waypoint study,
10:50we know that it is just as effective and safe
10:53also in subjects affected by chronic rhinosinusitis with nasal polyposis.
10:59This is certainly an important milestone for us
11:04that allows us to progress in our research and development
11:09of new therapeutic targets in the field of respiratory and immunological precision medicine.
11:21There are 20 million cancer diagnoses carried out every year around the world,
11:27a number destined to increase according to projections in 2050,
11:32with 77% more new cases, in fact, compared to 2022.
11:38Despite the continuous progress in the field of research,
11:41millions of people affected by cancer see their lives turned upside down
11:45due to the pathology and therapeutic paths
11:48both necessary and tiring from a physical and emotional point of view.
11:53With the intention of sharing new approaches to support patients and their families,
11:58a meeting was organized at the House of Representatives
12:01on the initiative of the Honorable Simona Loizzo,
12:04where the Manifesto for the Humanization of Cures in Oncology was presented,
12:08carried out by Merck, a leading company in the scientific and technological field,
12:13in collaboration with patient associations and reference clinics in the oncological field,
12:18then signed by all participants who have signed the commitment
12:22to promote concrete actions to bring the person back to the center of the ITER of cure
12:27and face the stigma associated with the disease.
12:30This manifesto, a manifesto shared by institutions, associations, pharmaceutical companies
12:36that provides for the enhancement of all essential levels of humanization.
12:41We are asked by patient associations, but we are also asked by doctors who work in this sector.
12:48To humanize means a medicine of proximity,
12:51which arrives at the patient's home as expected from the 6th mission of the PNRR Salute.
12:58The first step of the path that led to the drafting of the manifesto
13:02was to understand the need of the patient by giving him a voice
13:05and to understand at the same time the needs of their caregivers.
13:09And not only to understand and give a voice, but to react according to this will.
13:14And this is the objective of this manifesto.
13:17To give a voice, to give a solution to this voice,
13:20to have in this meeting not only the company, not only the institution,
13:24the medical society, the patient, but also the politician,
13:28is really something that gives me confidence that we can achieve that ambition
13:33to give a treatment not only to the disease, but also to the person.
13:36The National Counsellor of IHLA, Roberto Persio,
13:39explains how the oncological care for patients will be humanized thanks to this manifesto.
13:44For oncological patients it is essential a holistic care,
13:49that is, it does not have any disfigurements that put the patient in a condition
13:56to live fully on the path of disease and care.
14:00To do this, the psychological and oncological aspect is central.
14:05We have strongly supported this manifesto
14:10to always have a psychoncology available in the patient's life.
14:23Pre-death experiences, phenomenology and changes.
14:27This is the title of the agreement that wanted to deepen a complex and fascinating topic
14:32like that of pre-death experiences and extracorporeal experiences.
14:37Phenomena that, although they have been documented in various cultures and historical eras,
14:42continue to arouse great interest both in the scientific world and in the religious one.
14:47Here we try to find answers, to go into science and do science,
14:52and with more people, physical, medical,
14:57and all the people who can help to contribute to these phenomena,
15:04to give credibility, because there are, from the latest data,
15:08more than 10 years, 40,000 people who have declared these phenomena.
15:13Science must play its role, it must give concreteness to these phenomena
15:21and understand them, know them.
15:24We are trying in this multidisciplinary group to reach this goal,
15:29hard, but we will succeed.
15:32The agreement was born with the intention of deepening the topic,
15:35not only from the medical and neuroscientific point of view,
15:38but also with an anthropological and spiritual lens.
15:41Endless ODW was born with the intention of giving a safe place
15:47for people who have had pre-death experiences,
15:49to be able to tell and to be able to confront people
15:53who have had the same type of experience,
15:55in a safe and non-judging environment,
15:57because one of the big problems of this type of experience
16:01is that those who have lived it have problems integrating it
16:04as it is rejected by society.
16:07You can't talk about it, death is a taboo,
16:09and the pre-death experience is a taboo of the taboo.
16:12The event was hosted by the American Studies Center in Rome.
16:15A field in which there is probably still a lot to deepen,
16:20whose instruments are probably not yet adequate to understand
16:24what happens in those moments, in those particular circumstances,
16:28what is this phenomenon.
16:30And so I believe that as science does,
16:33that is, it proceeds through attempts, experiments, research,
16:38we do not know the limits of man's mind, of man's potentiality,
16:42and therefore experimenting, trying to understand what is there,
16:46in certain circumstances of our life,
16:48I believe it is a right element,
16:50and that honors the science that tries to understand.
17:01The European Commission approved Miriki Zumab,
17:04antagonist of the Interleukin 23p19,
17:07for the treatment of Crohn's disease in an active phase,
17:10from moderate to severe in adult patients
17:13who have had an inadequate response,
17:15have lost their response or are intolerant results
17:18to conventional therapy or a biological treatment.
17:21The drug has already been approved in 2024 in Italy
17:25by the Agency for Drug Treatment for Adults
17:28with active ulcerative colitis, from moderate to severe,
17:31and acts by targeting a specific protein,
17:34the Interleukin 23p19,
17:37key factor of intestinal inflammation in Crohn's disease,
17:41which is associated with progressive intestinal damage,
17:43disability and worsening of quality of life.
17:46But what is more specific about this pathology
17:49and how many suffer from it in Italy?
17:51Crohn's disease is a chronic inflammation of the intestine,
17:55characterized by an inflammation
17:58completely thick of the intestinal wall,
18:00it can affect any tract of the intestine,
18:03more frequently the ilioterminal and the right colon,
18:07and affects about 100,000 people in Italy.
18:10It is part of the group of chronic intestinal inflammatory diseases,
18:13Crohn's disease and ulcerative colitis,
18:15of which more or less 250,000 people in Italy are affected.
18:19The causes of Crohn's disease are still partially known.
18:23It is a multifactorial pathogenesis disease
18:27in which individuals who are predisposed
18:30in a genetic sense,
18:32at a certain point in their life,
18:34due to environmental factors
18:36that have not yet been clarified,
18:38but that still act by modifying the intestinal bacteria,
18:42well, in these individuals,
18:44in young or young adults,
18:46at a certain point,
18:48an inflammatory, chronic, recidivist response is born,
18:52which then gradually determines the intestinal damage
18:55and the progressive loss of function of the intestine
18:58if it does not intervene early.
19:00And it is essential to recognize it soon
19:02to be able to start the most effective treatments,
19:05because before you intervene,
19:07before you prevent the progression of the disease.
19:11The Mirichizumab has just been approved,
19:13which is a monoclonal antibody
19:15that selectively blocks the interleukin-23,
19:18this is a drug that manages to,
19:21first of all, induce the patients in remission,
19:25to improve endoscopy,
19:27so not only to send them in endoscopic response,
19:31but also in endoscopic remission,
19:33and it is also able to, in the long run,
19:37maintain clinical remission,
19:40improving the quality of life.
19:42In fact, patients often tend to have symptoms
19:45such as chronic diarrhea, abdominal pain and intestinal urgency,
19:49which have a strong impact on their psychological well-being
19:52and on their sociality.
19:54Many patients, then, Lilli specifies,
19:56do not reach complete remission,
19:58despite the treatments,
20:00or do not keep the disease under control in the long run.
20:03It is therefore necessary to act with target treatments
20:06that can represent a turning point
20:08in the management of the disease and of the symptomatology.
20:11The approval by the European Commission
20:14therefore represents an important advancement
20:16in the management of Crohn's disease.
20:18A decision to which it has mainly come
20:21based on the results of the randomized study,
20:23checked with placebo, of Phase 3, Vivid 1,
20:27and therefore of the Vivid 2 study,
20:29which evaluates the effectiveness and safety of the drug
20:32up to 3 years in adults with Crohn's disease
20:35from moderate to severe.
20:37In particular, it has been shown how patients
20:40who obtain a clinical response in 12 weeks
20:44and then reach a complete remission of the symptoms
20:48in one year, reach almost 50%.
20:52And above all, we have seen how in these patients
20:55the remission is characterized by a remission
20:58without the need for corticosteroid therapy,
21:01which is one of the therapies that we try to avoid
21:06due to the important side effects
21:09that corticosteroid therapies can give.
21:12New clinical points have also been taken into account,
21:16such as the evacuation urgency,
21:18which results show how,
21:21already from the first weeks of treatment,
21:25you can have a reduction of this symptom
21:29and therefore the improvement
21:31consequently of the patient's quality of life.
21:34The data instead deriving from Vivid 2
21:37have shown how those patients
21:39who reach the end of the first year of these
21:42about 80-90% then remain in remission,
21:46which means that if this therapy works,
21:49it works for a long period of time,
21:53so there is the possibility of treating these patients
21:56for a long time with excellent results.
21:59What changes then for patients and doctors
22:01with the extension of the approval of the MiriKi Zumab
22:04also for Crohn's disease?
22:06It certainly allows doctors and patients
22:10to have a new weapon
22:12with which it is possible to block the disease.
22:15It must be remembered that in the clinical studies
22:18the MiriKi Zumab has been used
22:21not only in naive patients,
22:23but also in patients who have failed
22:25more lines of treatment.
22:27This is a very important aspect
22:29because today we have patients
22:31that we define as difficult to treat,
22:33they have failed all therapies,
22:35so drugs like this are certainly welcome.
22:39Thanks to a better knowledge of the biology
22:42of the mammary tumor,
22:44which has allowed us to understand
22:46that there are at least three different subtypes
22:48of this carcinoma with different prognosis,
22:50different treatment needs
22:52and thanks to the innovation in the therapeutic field,
22:54a significant improvement
22:56of the life expectancy of patients
22:58with metastatic mammary tumor has been determined.
23:01The only subtype in which there has not been
23:03an improvement of survival
23:05is the so-called triple negative metastatic mammary tumor.
23:08And it is precisely in this subgroup of patients
23:10that this new drug
23:12that we call Govitegan
23:14has shown to improve
23:16the life expectancy,
23:18therefore to improve survival,
23:20to improve the time
23:22in which we can keep under control
23:24the metastatic disease
23:26and also to improve the quality of life
23:28compared to standard chemotherapy treatments.
23:32This drug, Sacchituzuan Govitegan,
23:34can also be used
23:36in an earlier stage
23:38of the history of these women
23:40with the so-called triple negative mammary tumor
23:42and therefore we expect
23:44that this earlier use
23:46can further improve
23:48the therapeutic results
23:50obtained so far.
23:52However, Sacchituzuan Govitegan
23:54also has a new indication
23:56that the possibility of using it
23:58also in the subgroup with
24:00positive hormonal receptors
24:02which constitutes the majority
24:04of cases of metastatic mammary carcinoma.
24:06Also in these patients
24:08compared to standard chemotherapy
24:10this innovative drug
24:12which is a conjugated antibody
24:14has shown to improve
24:16both survival and quality of life.
24:18So it is an important therapeutic option
24:20for practically
24:22most women
24:24who today live in Italy
24:26with a diagnosis of metastatic mammary carcinoma.
24:28With the GILAD meeting
24:30for women, new prospects
24:32in the metastatic carcinoma
24:34held in Milan, GILAD Science Italy
24:36celebrated the double result
24:38obtained with the indication extension
24:40of the drug.
24:42Our mission from the beginning,
24:44from the age of 35,
24:46is to revolutionize the path of treatment
24:48of serious diseases.
24:50We have done it in HIV,
24:52we have done it in hepatitis, in COVID,
24:54but also on oncology and mato-oncology.
24:56With a therapy, a conjugated antibody
24:58that is truly innovative,
25:00the metastatic carcinoma is triple negative.
25:02With that, we have already helped
25:04to treat about 2,000 women
25:06in Italy.
25:08But obviously this path continues
25:10with what we are announcing today.
25:12But it will also continue in the future
25:14because we also want to continue
25:16to strengthen our commitment in this area of solid oncology.
25:18We currently have
25:20about 30 clinical studies
25:22globally, 15 here in Italy
25:24where we do a lot of research.
25:26We hope by 2030
25:28to arrive with 29 indications
25:30both in the breast tumor
25:32as well as in the lung tumor,
25:34in the genitourinary
25:36and other types of tumors.
25:38This was our
25:40latest news.
25:42To contact us,
25:44you can write to
25:46salute-adienecronos.com
25:48Thank you for following us
25:50and see you in the next episode.
25:54www.salute-adienecronos.com